News Related to Upper Respiratory Tract Infections

Related coverage linked through entity extraction aliases.

EU panel backs Sanofi’s tolebrutinib for secondary progressive multiple sclerosis

Apr 24, 2026

The EMA’s CHMP recommended approval of Sanofi’s Cenrifki (tolebrutinib) for non-relapsing secondary progressive multiple sclerosis. The phase 3 HERCULES study showed reduced disability progression, while liver injury remains an identified safety risk.

Lebrikizumab and Stapokibart Show Efficacy in Pediatric Atopic Dermatitis Trials

Mar 16, 2026

Two phase 3 trials demonstrate significant improvements in skin clearance and disease severity for children and adolescents with moderate-to-severe atopic dermatitis treated with targeted biologics.